Aumenta le possibilità di ricevere una risposta da questo datore di lavoro
Il tuo curriculum e una lettera di presentazione personalizzati, che corrispondono esattamente a ciò che sta cercando.
Genentech, a Roche company, offers a 2027 Summer Intern position in Translational Safety (Computational Toxicology) in South San Francisco. This on-site, intensive 12-week full-time internship provides a stipend and hands-on projects in a world-class biotech environment.
The program targets students pursuing or holding Master’s/PhD degrees, with emphasis on bioinformatics, computational biology, and data science skills. Start dates in May/June, with collaboration across safety sub-functions.
Development Sciences (DevSci) spans the entire drug discovery and development cycle — from early stage research to drug commercialization. Part of the drug development pipeline in DevSci includes the preclinical safety evaluation of candidate therapeutic molecules by toxicologists and pathologists in the Translational Safety (TS) department in order to enable further evaluation in humans. Translational Safety is an integral part of DevSci. We contribute to the organization’s success by providing scientific insights and ensuring the safety of molecules that advance through the pipeline to patients. We do this to support the DevSci vision to deliver the right drug in the right dose to the right patient. We are also committed to providing better outcomes for our people, patients, business, and communities by advancing and boldly championing diversity, equity, and inclusion in our work. The Translational Safety organization is composed of several integrated sub-functions. This summer intern project falls within the Computational Toxicology sub-function. The Computational Toxicology group enables early and accurate compound safety profiling by leveraging all relevant data (in vitro, ex vivo, in vivo), advanced analytics and computational modeling while closely working with other Translational Safety subfunctions such as Investigative Toxicology and Complex In Vitro Systems and subfunctions within gRED Computational Sciences Center of Excellence (CS CoE) organization.
This internship position is located in South San Francisco, on-site.
Intensive 12-weeks, full-time (40 hours per week) paid internship. Program start dates are in May/June (Summer). A stipend, based on location, will be provided to help alleviate costs associated with the internship. Ownership of challenging and impactful business-critical projects. Work with some of the most talented people in the biotechnology industry.
Must be pursuing a Master's Degree (enrolled student). Must have attained a Master's Degree. Must be pursuing a PhD (enrolled student).
Complements our culture and the standards that guide our daily behavior & decisions: Integrity, Courage, and Passion.
The expected salary range for this position based on the primary location of California is $41.00-$52.00 hourly.
Actual pay will be determined based on experience, qualifications, geographic location, and other job-related factors permitted by law.
Genentech is an equal opportunity employer. It is our policy and practice to employ, promote, and otherwise treat any and all employees and applicants on the basis of merit, qualifications, and competence. The company's policy prohibits unlawful discrimination, including but not limited to, discrimination on the basis of Protected Veteran status, individuals with disabilities status, and consistent with all federal, state, or local laws.
If you have a disability and need an accommodation in relation to the online application process, please contact us by completing this form Accommodations for Applicants.
Genentech, a member of the Roche group and founder of the biotechnology industry, is dedicated to pursuing groundbreaking science to discover and develop medicines for people with serious and life‑threatening diseases. To solve the world's most complex health challenges, we ask bigger questions that challenge our industry and the boundaries of science to transform society. Our transformational discoveries include the first targeted antibody for cancer and the first medicine for primary progressive multiple sclerosis. The next step is yours.